CD63 and cancer: CRISPR/Cas9 knockout of CD63 in Epstein-Barr virus infected cancer cells resulted in reduced secretion of EVs that were positive for the viral protein LMP1, and severely impaired packaging of those vesicles, concomitant with a disruption in the perinuclear localization of LMP1 (Hurwitz et al., 2017).